A Multicenter Cancer Biospecimen Collection Study

Launched by COFACTOR GENOMICS, INC. · Aug 10, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on collecting tumor samples from patients with specific types of cancer, including head and neck, lung, and breast cancers, among others. The goal is to gather these samples, along with related health information, to help develop and improve diagnostic tests that can be used to better understand and treat these cancers. If you are an adult (18 years or older) who has either received or is scheduled to receive a particular type of cancer treatment known as anti-PD-1/PD-L1 immunotherapy, and you have had or will have a biopsy of your tumor before starting this treatment, you may be eligible to participate.

Participants in the study will provide tumor samples and some health information, and they will be asked to give their consent to take part. It’s important to note that those who cannot give consent or who have not been diagnosed with one of the specific cancers listed will not be eligible. By participating in this study, you could contribute to important research that may improve cancer diagnosis and treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Subject must have a disease of interest. Specifically, subject must have one of:
• • 1. head and neck squamous cell carcinoma (HNSCC)
• • 2. non-small-cell lung cancer (NSCLC)
• • 3. small cell lung cancer (SCLC)
• • 4. urothelial carcinoma (UCC)
• • 5. gastric or gastroesophageal junction adenocarcinoma
• • 6. cervical cancer
• • 7. esophageal squamous cell carcinoma (ESCC)
• • 8. triple-negative breast cancer (TNBC)
• • 9. hepatocellular carcinoma (HCC)
• • 10. renal cell carcinoma (RCC)
• • 11. colorectal cancer (CRC)
• • 2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1/PD-L1 immunotherapy for treatment of their cancer.
• • 3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy.
• • 4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy.
• • 5. Willing to provide electronic informed consent per IRB-approved protocol.
• • 6. Able to speak, read, and comprehend English fluently.
• • 7. Subject is 18 years of age or older.
• • 8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.
• Exclusion Criteria:
• • 1. Inability or unwillingness to provide informed consent.
• • 2. Subject who does/did not have one of the cancers listed above (other histologies).
• • 3. Subject has already participated in this trial.